Roll over image to zoom in The Ordinary Face Serum Set! Ascorbic Acid 8%+Alpha Arbutin 2%! Hyaluronic Acid 2%+B5! Glycolic Acid 7% Toning Solution! Help Fight Visible Blemishes And Improved Skin Radiance!

$39.50

  • Hydrating Serum: Hyaluronic acid helps retain moisture for improved hydration and radiance.
  • Exfoliating Formula: Glycolic acid gently removes dead skin cells to reveal smoother, brighter skin.
  • Vitamin C and Peptides: Ascorbic acid and peptides help brighten and even out skin tone.
  • Blemish Control: Alpha arbutin helps reduce the appearance of blemishes and prevent future breakouts.
  • For All Skin Types: Suitable for combination skin types and can be used daily for best results.
Category:
Compare

Description

Set Includes Ascorbic Acid 8%+Alpha Arbutin 2%! Hyaluronic Acid 2%+B5! Glycolic Acid 7% Toning Solution! Help Fight Visible Blemishes And Improved Skin Radiance! Help Fight Visible Blemishes And Improved Skin Radiance! Glycolic Acid 7% Toning Solution from The Ordinary is a toning solution that offers mild exfoliation for improved skin radiance and visible clarity. The Ordinary’s Ascorbic Acid 8% + Alpha Arbutin 2% is a water-free, stable solution. This formula offers a combination of 8% Ascorbic Acid and 2% Alpha-Arbutin that work together to visibly brighten the look of skin while also targeting the appearance of dark spots and multiple signs of skin aging. Hyaluronic Acid 2% + B5 from The Ordinary is formulated with a combination of low, medium, and high molecular-weight hyaluronic acid, as well as a next-generation hyaluronic acid crosspolymer, at a combined concentration of 2% for multi- depth hydration.

Additional information

Weight 17.1 oz
Dimensions 7.72 × 6.14 × 2.8 in

Reviews

There are no reviews yet.


Be the first to review “Roll over image to zoom in The Ordinary Face Serum Set! Ascorbic Acid 8%+Alpha Arbutin 2%! Hyaluronic Acid 2%+B5! Glycolic Acid 7% Toning Solution! Help Fight Visible Blemishes And Improved Skin Radiance!”

General Inquiries

There are no inquiries yet.